Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04730258 · ClinicalTrials.gov registry record · Phase 1
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Treadwell Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 9
- Study locations
NCT04730258: Active Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Treadwell Therapeutics.
NCT04730258 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is active but no longer recruiting, run by Treadwell Therapeutics. The registered enrollment target is 72 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (38% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04730258, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Treadwell Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
Primary Outcome
The number of subjects who experience an adverse event that was possibly related to study drug
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG CFI-400945
Study Locations (9)
California
- City of Hope - Duarte
- University of California Davis Comprehensive Cancer Center - Sacramento
Kentucky
- Norton Cancer Institute - Saint Matthews - Louisville
New York
- New York Presbyterian Weill Cornell Medical Center - New York
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Texas
- The University of Texas MD Anderson Cancer Centre - Houston
Alberta
- University of Alberta - Edmonton
Ontario
- Princess Margaret Cancer Center - Toronto
Other
- Queen Mary Hospital - Hong Kong
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-04-16 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
What the registry record for NCT04730258 still lists
NCT04730258 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (38% lower).
The record links to 6 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.
NCT04730258 lists 9 locations in 8 states (California, Kentucky, New York).
Frequently Asked Questions
What is clinical trial NCT04730258 about?
NCT04730258 is a clinical study titled "A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML". The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
What is the current status of trial NCT04730258?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2021-04-16. Estimated completion is 2026-01.
What conditions does trial NCT04730258 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS.
What interventions are being tested in trial NCT04730258?
The interventions under investigation include: Azacitidine (DRUG), CFI-400945 (DRUG).
Who is sponsoring clinical trial NCT04730258?
This trial is sponsored by Treadwell Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04730258 being conducted?
This trial has 9 study locations across California, Kentucky, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04730258's enrollment target sits among peer trials
72 107th of 306 higher than 198 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
- NCT03747458 · 72 participants · Phase 3
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI